Study on IBI363 for Patients with Advanced Solid Tumors

Inclusion Criteria

• Ability to understand and provide written consent to participate in the study, including all required evaluations and procedures.
• Male or female participants aged 18 years or older.
• Good overall health with an ECOG performance status of 0 or 1, indicating full activity or some restriction in strenuous activities.
• Expected to live for at least 3 more months.

Exclusion Criteria

• Poor bone marrow or organ function.
• Have received chemotherapy or targeted therapy within 2 weeks or 5 plasma half-lives before starting the study drug. Nitrosoureas and mitomycin C must not have been received within 6 weeks before the first dose. No anti-cancer monoclonal antibodies within 4 weeks before the first dose.
• Have received live vaccines within 28 days before starting the study drug or plan to receive any during the study.
• Have unresolved side effects from previous cancer treatments that are not mild (Grade 0 or 1) except for hair loss, fatigue, or skin changes that are not considered risky.
• Have had major surgery within 4 weeks before starting the study drug, or plan to have major surgery during the study, or have severe unhealed wounds or injuries.